GSK plcLSE: GSK

GSK: Director/PDMR Shareholding

· Issued by GSK plc via RNS

Summary by 6ix AI

GSK plc, a global biopharma company, said senior managers, non-executive directors and people closely associated with some of them acquired GSK shares by reinvesting dividends paid to shareholders on October 8, 2026.

Key details

  • Executives bought ordinary shares at £17.5904 each on October 8, 2026 on the London Stock Exchange. They included Chief Executive Officer Luke Miels (23.331 shares), David Redfern, President Corporate Development (6,532.657), and Regis Simard, President, Global Supply Chain (2,999.067).
  • Other executive acquisitions at £17.5904 included Philip Thomson, President, Global Affairs (2,707.449 shares), Chief Scientific Officer Tony Wood (2,558.851) and James Ford, SVP and Group General Counsel (2,014.345).
  • Non-executive directors acquired American Depositary Shares (US-listed GSK shares) at $46.5883 each on October 9, 2026 on the New York Stock Exchange. These included Senior Independent Non-Executive Director Charles Bancroft (412) and Dr Vishal Sikka (136).
  • People closely associated with executives also acquired ordinary shares at £17.5904: Neil Falkingham, linked to Lynn Baxter, President, Europe (169.615 shares), and Kate Thomson, linked to Philip Thomson (112.233).

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/directorpdmr-shareholding-1559

Watch GSK's latest callGSK (LSE:GSK) Q2 2026 Earnings Call · Replay · Jul 28Read the transcript of GSK (LSE:GSK) Q2 2026 Earnings Call
GSK PLC
13 October 2026
 

GSK plc (the ‘Company’)

Transaction notification

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Luke Miels

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

23.331

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Lynn Baxter

b)

Position/status

President, Europe

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

297.818

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Mike Crichton

b)

Position/status

President, International

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

1.100

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

2,014.345

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Nina Mojas

b)

Position/status

President, Global Product Strategy

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

246.181

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Roanne Parry

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

1.400

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

6,532.657

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

2,999.067

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

2,707.449

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

1,204.461

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

2,558.851

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Neil Falkingham

b)

Position/status

PCA of Lynn Baxter (President, Europe)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

169.615

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Kate Thomson

b)

Position/status

PCA of Philip Thomson (President, Global Affairs)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.5904

112.233

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-08

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Elizabeth McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

41

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

412

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

32

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

47

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Harry Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

45

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Jeannie Lee

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

27

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5883

136

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

GSK plc on 6ix

Story so far

Earlier from GSK

All GSK news releases